Real-World Evidence Needs for Treatment Sequence Disease Modelling in Refractory Inflammatory Bowel Disease

被引：0
|
作者：
Kodjamanova, P. [1 ]
Sanon, M. [2 ]
Dimova, M. [3 ]
Wu, E. [2 ]
Atanasov, P. [4 ]
机构：
[1] Amaris Consulting, Real World Evidence, London, England
[2] Janssen Global Serv, Global Market Access, Raritan, NJ USA
[3] Janssen Global Serv, HTA Modelling, Horsham, PA USA
[4] Amaris Consulting, Real World Evidence, Barcelona, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1437
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1263
引用
收藏
页码：i2288 / i2288
页数：1
相关论文
共 50 条
  • [41] REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
    Schreiber, Stefan
    Dignass, Axel
    Peyrin-Biroulet, Laurent
    Mosli, Mahmoud
    Hather, Greg
    Demuth, Dirk
    Blake, Aimee
    Curtis, Rebecca
    Khalid, Javaria Mona
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S57 - S58
  • [42] Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study
    Miyazaki, Celine
    Ishii, Yukata
    Stelmaszuk, Natalia M.
    CLINICAL RHEUMATOLOGY, 2022, 41 (03) : 741 - 755
  • [43] Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study
    Celine Miyazaki
    Yutaka Ishii
    Natalia M. Stelmaszuk
    Clinical Rheumatology, 2022, 41 : 741 - 755
  • [44] Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Holmgren, Johanna
    Klintman, Daniel
    Marsal, Jan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (11) : 1389 - 1401
  • [45] Real-world assessment of biological treatment of inflammatory bowel disease at an Austrian Referral Centre: the ULTIMATE study
    Groechenig, H. P.
    Walter, E.
    Redl, A.
    Bresztowanszky, M.
    Steidl, K.
    Siebert, F.
    Novacek, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S266 - S267
  • [46] Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting
    Degli Esposti, Luca
    Perrone, Valentina
    Sangiorgi, Diego
    Saragoni, Stefania
    Dovizio, Melania
    Caprioli, Flavio
    Rizzello, Fernando
    Daperno, Marco
    Armuzzi, Alessandro
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (01) : 29 - 34
  • [47] Iron deficiency anemia impacts disease progression and healthcare resource consumption in patients with inflammatory bowel disease: a real-world evidence study
    Fiorino, Gionata
    Colombel, Jean-Frederic
    Katsanos, Kostas
    Mearin, Fermin
    Stein, Juergen
    Andretta, Margherita
    Antonacci, Stefania
    Arenare, Loredana
    Citraro, Rita
    Dell'Orco, Stefania
    Esposti, Luca Degli
    de Arellano Serna, Antonio Ramirez
    Morin, Neige
    Koutroubakis, Ioannis E.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [48] Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data
    Goss Sawhney, Tia
    Dobes, Angela
    O'Charoen, Sirimon
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [49] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Hsu, Diane
    Lee, Justin
    Kotzen, Alison
    Bensen, Rachel
    Goyal, Alka
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S73 - S74
  • [50] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Anjur, Kavya
    Neiman, Nicole
    Kotzen, Alison
    Pond, Stephen
    Goyal, Alka
    GASTROENTEROLOGY, 2022, 162 (07) : S826 - S826
12345